Advanced Malignancies Clinical Trial
Official title:
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies
Verified date | November 2018 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).
Status | Completed |
Enrollment | 59 |
Est. completion date | April 5, 2011 |
Est. primary completion date | September 1, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Have a histologically or cytologically confirmed metastatic and/or advanced malignancy (including lymphomas but excluding malignancies with extensive bone marrow involvement such as leukemias and multiple myeloma) for which standard treatment does not offer curative or life-prolonging potential. 2. Aged 18 years or more. 3. Eastern Cooperative Oncology Group performance status 0 or 1. 4. Have an expected survival longer than 3 months from enrollment in the study. 5. Radiographically or clinically evaluable tumor. 6. Suitable venous access for the conduct of blood sampling. 7. Recovered from the reversible effects of prior antineoplastic therapy (with the exception of alopecia and grade 1 neuropathy) with at least 4 weeks elapsed since the last exposure to cytotoxic chemotherapy or to radiotherapy and at least 6 weeks elapsed since exposure to nitrosoureas or mitomycin C. Participants treated with fully human monoclonal antibodies must not have received treatment with such antibodies for at least 6 weeks, and those treated with chimeric monoclonal antibodies must not have received treatment with such antibodies for at least 4 weeks. Participants treated with noncytotoxic small molecule drugs (eg, tyrosine kinase inhibitors, such as Tarceva® [erlotinib], and hormonal agents, such as Femara® [letrozole]) must not have received treatment with these drugs for at least 2 weeks before the first dose of alisertib was given. 8. Male participants must use an appropriate method of barrier contraception and inform any sexual partners that they must also use a reliable method of contraception from the time of informed consent until 3 months after the last dose of study treatment. 9. Female participants must be postmenopausal at least 1 year, OR surgically sterile, OR if of childbearing potential, agree to 2 effective methods of nonhormonal contraception, or agree to completely abstain from heterosexual intercourse. 10. Able to give written consent. Exclusion Criteria: 1. Pregnant or lactating. 2. Major surgery or serious infection within the 28 days preceding the first dose of study treatment. 3. Life-threatening or uncontrolled medical illness unrelated to cancer. 4. Ongoing nausea or vomiting of any severity. 5. >Grade 1 diarrhea. Participants who require ongoing therapy with an antimotility agent to control diarrhea to a Grade 1 or lower level are not allowed to participate in this trial. 6. Known gastrointestinal disease or gastrointestinal procedures that could interfere with the oral absorption or tolerance of MLN8237. 7. History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe chronic obstructive pulmonary disease. 8. Difficulty swallowing capsules. 9. Inability to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose of MLN8237. 10. Received more than 4 previous cytotoxic chemotherapeutic regimens, including regimens used as adjuvant or neo-adjuvant therapies (in participants with metastatic breast cancer, a total of 5 previous cytotoxic chemotherapeutic regimens is permitted). 11. Prior treatment with high-dose chemotherapy, defined as chemotherapy requiring the use of peripheral blood or bone marrow stem cell support for hematopoietic reconstitution. 12. Prior treatment with radiation therapy involving =25% of the hematopoietically active bone marrow for the distribution of active bone marrow in adults). 13. Clinical and/or radiographic evidence of cerebral metastases. However, participants who have a history of central nervous system metastasis but who have no radiographic or clinical evidence of residual tumor (eg, following complete surgical resection or stereotactic radiosurgery) are not excluded from participation in this study. 14. Absolute neutrophil count(ANC) < 1500/mm^3; platelet count< 100,000/mm^3. 15. Serum creatinine >1.6 mg/dL or a measured or estimated (Cockcroft-Gault formula) creatinine clearance <40 mL/min 16. Bilirubin >1.5 times the upper limit of the normal range (ULN); aspartate aminotransferase(AST)/alanine aminotransferase(ALT) >2.5 times the ULN, and alkaline phosphatase(ALP) >2.5 times the ULN. Both the AST and ALP could be elevated up to 5 times the ULN if their elevation could be reasonably ascribed to the presence of metastatic disease to liver and/or to bone; however, the ALT in all circumstances must have been <2.5 times the ULN. 17. Abnormalities on 12-lead electrocardiogram considered by the investigator to be clinically significant or baseline prolongation of the rate-corrected QT interval (eg, repeated demonstration of QTc interval >450 milliseconds). 18. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C. 19. Less than 4 weeks between the last dose of an investigational agent and the first dose of MLN8237. 20. Admission or evidence of benzodiazepine dependence or abuse and/or alcohol abuse or an inability to restrict consumption of alcohol to no more than 1 standard unit of alcohol per day during the study and for 30 days from the last dose of study treatment. 21. Activated partial thromboplastin time (aPTT) and/or prothrombin time (PT) exceeding the upper limit of the normal range. 22. Known bleeding diathesis or history of abnormal bleeding. 23. Ongoing therapy with an anticoagulant (e.g., aspirin, plavix, coumadin). |
Country | Name | City | State |
---|---|---|---|
Spain | Ciutat Sanitaria Vall d'Hebron - Servicio de Oncologia | Barcelona | |
Spain | H. Clínico Universitario de Valencia | Valencia |
Lead Sponsor | Collaborator |
---|---|
Millennium Pharmaceuticals, Inc. |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Percentage of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1 | A blood sample was collected prior to alisertib dosing for the purpose of genotyping for polymorphisms in UGT1A1. The percentage of participants in the polymorphism categories: wt/wt, wt/*28, *28/*28, *28/wt, *28/other and other/other is reported. wt=wild type. *28 polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression. | Cycle 1: Pre-dose | |
Primary | Number of Participants With Dose-Limiting Toxicity (DLT) | DLT was evaluated using the National Cancer Institutes Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0; defined as any of the following events related to alisertib therapy: Grade 4 neutropenia lasting for =7 consecutive days during recovery Grade 4 neutropenia with fever and/or infection Confirmed platelet count <25,000/mm^3 =Grade 3 nausea and/or emesis despite the use of an antiemetic prophylaxis =Grade 3 diarrhea that occurred despite therapy with loperamide Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (< 1 week) Grade 3 fatigue Treatment delay of >1 week because of a failure of adequate hematologic or nonhematologic recovery from the previous cycle of treatment. Other alisertib-related nonhematologic toxicities = Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib. |
First dose through 30 days following the last dose of study drug (up to 730 days) | |
Primary | Maximum Tolerated Dose (MTD) of Alisertib | The MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants. | Signing of the Informed Consent through 30 days following the last dose of study drug (up to 730 days) | |
Secondary | Cmax: Maximum Observed Concentration for Alisertib 7 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7 | ||
Secondary | Tmax: Time of First Occurrence of Cmax for Alisertib 7 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7 | ||
Secondary | AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 7 Day Dosing | Cycle1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7 | ||
Secondary | Terminal Half-Life (t1/2) for Alisertib 7 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7 or 8 (BID arms) | ||
Secondary | Accumulation Ratio (Rac) for Alisertib 7 Day Dosing | Rac for Day 7=AUCt Day 7/AUCt Day 1. | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7 | |
Secondary | Peak/Trough Ratio for Aliserib 7 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7 | ||
Secondary | CLss/F: Apparent Oral Clearance at Steady State 7 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7 | ||
Secondary | Cmax: Maximum Observed Concentration for Alisertib 14 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14 | ||
Secondary | Tmax: Time of First Occurrence of Cmax for Alisertib 14 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14 | ||
Secondary | AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 14 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14 | ||
Secondary | Terminal Half-Life (t1/2) for Alisertib 14 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14 | ||
Secondary | Accumulation Ratio (Rac) for Alisertib 14 Day Dosing | Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1. | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14 | |
Secondary | Peak/Trough Ratio for Aliserib 14 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14 | ||
Secondary | CLss/F: Apparent Oral Clearance at Steady State 14 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14 | ||
Secondary | Cmax: Maximum Observed Concentration for Alisertib 21 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21 | ||
Secondary | Tmax: Time of First Occurrence of Cmax for Alisertib 21 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21 | ||
Secondary | AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 21 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21 | ||
Secondary | Terminal Half-Life (t1/2) for Alisertib 21 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 21 | ||
Secondary | Accumulation Ratio (Rac) for Alisertib 21 Day Dosing | Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1. Rac for Day 21=AUCt Day 21/AUCt Day 1. | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21 | |
Secondary | Peak/Trough Ratio for Aliserib 21 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21 | ||
Secondary | CLss/F: Apparent Oral Clearance at Steady State 21 Day Dosing | Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21 | ||
Secondary | Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 7 Day Dosing | Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement. | Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Day 7, 6 and 24 hours post-dose. | |
Secondary | Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 14 Day Dosing | Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement. | Cycle 1: Pre-dose (Baseline) and Day 1 and 7, 6 hours post-dose; Day 14, 6 and 24 hours post-dose | |
Secondary | Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 21 Day Dosing | Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement. | Cycle 1: Pre-dose (Baseline) and Day 7, 14 and 21, 6 hours post-dose | |
Secondary | Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 7 Day Dosing | Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement. | Cycle 1: Day 1, 6 hours post-dose; Days 7 6 and 24 hours post-dose; Day 21: 6 hours post-dose | |
Secondary | Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 14 Day Dosing | Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement. | Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Days 7 and 14, 6 and 24 hours post-dose | |
Secondary | Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 21 Day Dosing | Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement. | Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Days 7 and 14, 6 and 24 hours post-dose; Day 21: 6 hours post-dose | |
Secondary | Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 7 Day Dosing | Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement. | Cycle 1: Pre-dose (Baseline) and Days 1 and 7, 6 hours post-dose | |
Secondary | Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 14 Day Dosing | Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement. | Cycle 1: Pre-dose (Baseline) and Day 7, 6 hours post-dose | |
Secondary | Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 21 Day Dosing | Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement. | Cycle 1: Pre-dose (Baseline) and Days 7 and 21, 6 hours post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Completed |
NCT00948961 -
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
|
Phase 1/Phase 2 | |
Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
Terminated |
NCT02265510 -
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03907969 -
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
|
Phase 1/Phase 2 | |
Completed |
NCT03241173 -
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT02923349 -
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04025957 -
A Study of SHR-1501 in Patients With Advanced Tumors
|
Phase 1 | |
Recruiting |
NCT05048134 -
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT06038058 -
A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00611793 -
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
Not yet recruiting |
NCT05987605 -
Clinical Study of 1A46 Drug Substance
|
Phase 1 | |
Terminated |
NCT02608268 -
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT03277352 -
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05577182 -
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT04831996 -
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
|
Phase 1 | |
Recruiting |
NCT06468098 -
A Study of IBI363 in Subjects With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT02737501 -
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
|
Phase 3 | |
Completed |
NCT03158272 -
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
|
Phase 1 |